CRTE7A2-01 / CorreGene - LARVOL DELTA

CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Corregene Biotechnology Co., Ltd

Metastases • New P1 trial • Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor

CRTE7A2-01: A HPV-16 E711-19 Specific TCR Targeting HPV-Related Cancers (ASGCT 2023) - P1 | "Furthermore, CRTE7A2 shows excellent safety in vivo.We are now conducting a single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D (NCT05122221)."

Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Infectious Disease • Oncology • Solid Tumor • HLA-A • IFNG

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Corregene Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2021 ➔ Jul 2022

Enrollment open • Trial initiation date • Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • HLA-A